Director-Affiliated Fund Files Intent to Sell $127.4M in Cogent Biosciences Shares
COGT has more than doubled off its 52-week low of $3.72.
Summary
A fund associated with a director of Cogent Biosciences has filed a Form 144 to sell 3.5 million shares, valued at $127.4 million, indicating a significant insider-affiliated disposition.
Key Events · Ownership and Investor Activity · COGT
-
Director-Affiliated Fund Files Intent to Sell
Fairmount Healthcare Fund II L.P., an entity associated with director Peter Harwin, filed a Form 144 to sell 3,500,000 shares of common stock.
-
Significant Proposed Sale Value
The proposed sale has an approximate market value of $127.4 million, representing a substantial portion of the company's market capitalization.
Analysis · COGT · Life Sciences
Fairmount Healthcare Fund II L.P., an entity associated with Peter Harwin, a director of Cogent Biosciences, has filed a Form 144 indicating its intent to sell 3,500,000 shares. This proposed sale, valued at approximately $127.4 million, represents a significant portion of the company's market capitalization. Such a large insider-affiliated disposition could signal a lack of confidence or a strategic portfolio adjustment by a key investor, potentially creating downward pressure on the stock.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COGT was trading at $39.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $3.72 to $43.73. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.